Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases
Cancer Treatment and Research Communications · 2026 · 49 · 101442
DOI: 10.1016/j.ctarc.2026.101442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yuting Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jiangxi Provincial People's Hospital the First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu Di…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Education Department of Jiangxi Province, Health Commission of Jiangxi Province.
Abstract (Originalsprache)
OBJECTIVE: To analyze the clinical features and related factors of acquired resistance to EGFR-TKI in patients with non-small cell lung cancer (NSCLC) and brain metastases, and to construct a prognostic prediction model. METHODS: A total of 186 NSCLC patients were retrospectively enrolled and divided into four groups based on EGFR-TKI resistance and brain metastasis status: resistant with brain metastases (n = 65), resistant without brain metastases (n = 65), sensitive with brain metastases (n = 28), and sensitive without brain metastases (n = 28). Univariate and multivariate logistic regression analyses were used to identify independent risk factors for resistance. A Cox proportional hazards model was applied to evaluate prognostic factors, and ROC curves were used to assess the predictive performance of the model. RESULTS: Multivariate analysis showed that non-classical EGFR mutations, TP53 co-mutations, MET amplification, CEA >5 μg/L, and third-generation EGFR-TKI therapy were independently associated with resistance (all P < 0.05), while anti-angiogenic therapy significantly reduced the risk of resistance. The median overall survival (14.0 vs. 38.0 months) and progression-free survival (9.0 vs. 26.0 months) were significantly shorter in the resistant group (P < 0.001). The number of brain metastases ≥3, ECOG PS ≥2, and T790M negativity were independent predictors of poor prognosis. The combined prediction model demonstrated good discriminative ability, with an AUC of 0.81 (95% CI: 0.76-0.86). CONCLUSION: This study clarifies the factors associated with EGFR-TKI resistance and prognostic characteristics in NSCLC patients with brain metastases. The constructed prediction model helps identify high-risk patients and provides a reference for formulating individualized treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Jiangxi Provincial People's Hospital the First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu District, Nanchang, Jiangxi, 330006, China; School of Laboratory Medicin…
- Department of Oncology, Jiangxi Provincial People's Hospital the First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu District, Nanchang, Jiangxi, 330006, China; Graduate School, Jiangxi Uni…
- Department of Oncology, Jiangxi Provincial People's Hospital the First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu District, Nanchang, Jiangxi, 330006, China.
- Department of Oncology, Jiangxi Provincial People's Hospital the First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Donghu District, Nanchang, Jiangxi, 330006, China. Electronic address: qinglins…
Förderung
- Education Department of Jiangxi Province
- Health Commission of Jiangxi Province
Zitieren
APA
Wang, Y., Li, X., Mao, Z., & Shen, Q. (2026). Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases. Cancer Treatment and Research Communications, 49, 101442. https://doi.org/10.1016/j.ctarc.2026.101442
Vancouver
Wang Y, Li X, Mao Z, Shen Q. Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases. Cancer Treatment and Research Communications. 2026;49:101442. doi:10.1016/j.ctarc.2026.101442
BibTeX
@article{Wang2026,
author = {Wang, Yuting and Li, Xia and Mao, Zhifang and Shen, Qinglin},
title = {Clinical features and multidimensional prognostic model of EGFR-TKI acquired resistance in NSCLC patients with or without brain metastases},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101442},
doi = {10.1016/j.ctarc.2026.101442}
}
EUVIMED